Agios Pharmaceuticals | AGIO - Interest Expense On Debt



Agios Pharmaceuticals reported 3.01M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Agios Pharmaceuticals 3.01M 10.05M Dec/2024
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Amgen USD 694M 29M Jun/2025
Arrowhead Research USD 24.38M 2.74M Jun/2025
Astellas Pharma 3.91B 320M Mar/2025
AstraZeneca 303M 126M Jun/2025
Bayer 495M 89M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Daiichi Sankyo 1.42B 5.66B Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Exelixis 23.4M 3.9M Sep/2023
Gilead Sciences USD 254M 6M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
Incyte USD 594K 66K Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
Merck USD 305M 8M Jun/2025
Moderna USD 1000K 0 Jun/2025
Novartis USD 289M 19M Jun/2025
Novartis USD 289M 14M Jun/2025
Pfizer USD 654M 0 Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Sarepta Therapeutics USD 5.23M 725K Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025